Skip to main content

Table 1 Baseline characteristics of enrolled patients

From: Assessment of Plasmodium falciparum anti-malarial drug resistance markers in pfk13-propeller, pfcrt and pfmdr1 genes in isolates from treatment failure patients in Democratic Republic of Congo, 2018–2019

Characteristics N % (95% CI) p
Age (years)    < 0.001
 0–5 172 36.3 (32.0–40.8)  
 6–14 124 26.2 (22.3–30.4)  
 15–49 154 32.5 (28.3–36.9)  
 50–76 24 5.1 (3.3–7.5)  
Total 474 100.0  
Sex    < 0.001
 Female 272 57.4 (52.8–61.9)  
 Male 202 42.6 (38.1–47.2)  
Total 474 100.0  
Anti-malarial used for initial episode    0.009
 ASAQ 196 41.4 (36.9–45.9)  
 AL 273 57.6 (53.0–62.1)  
 DP 5 1.1 (0.3–2.4)  
Total 474 100.0  
Enrolled patients per site    < 0.001
 Bolenge 88 18.6 (15.2–22.4)  
 Fungurume 83 17.5 (14.2–21.2)  
 Kabondo 20 4.2 (2.6–6.4)  
 Katana 143 30.2 (26.1–34.5)  
 Kingasani 113 23.8 (20.1–27.9)  
 Vanga 27 5.7 (3.8–8.2)  
Total 474 100.0  
Detection of P. falciparum by PCR    < 0.001
 Negative 110 23.2 (19.5–27.3)  
 Positive 364 76.8 (72.7–80.5)  
Total 474 100.0  
  1. AL artemether-lumefantrine, ASAQ artesunate-amodiaquine, DP dihydroartemisinin-piperaquine, N number